JP2023519962A5 - - Google Patents

Info

Publication number
JP2023519962A5
JP2023519962A5 JP2022559492A JP2022559492A JP2023519962A5 JP 2023519962 A5 JP2023519962 A5 JP 2023519962A5 JP 2022559492 A JP2022559492 A JP 2022559492A JP 2022559492 A JP2022559492 A JP 2022559492A JP 2023519962 A5 JP2023519962 A5 JP 2023519962A5
Authority
JP
Japan
Prior art keywords
sequence
antibody
sequence numbers
mertk
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022559492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519962A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/024970 external-priority patent/WO2021202590A1/en
Publication of JP2023519962A publication Critical patent/JP2023519962A/ja
Publication of JP2023519962A5 publication Critical patent/JP2023519962A5/ja
Withdrawn legal-status Critical Current

Links

JP2022559492A 2020-03-31 2021-03-30 抗mertk抗体及びその使用方法 Withdrawn JP2023519962A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063003070P 2020-03-31 2020-03-31
US63/003,070 2020-03-31
US202163165592P 2021-03-24 2021-03-24
US63/165,592 2021-03-24
PCT/US2021/024970 WO2021202590A1 (en) 2020-03-31 2021-03-30 Anti-mertk antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023519962A JP2023519962A (ja) 2023-05-15
JP2023519962A5 true JP2023519962A5 (OSRAM) 2024-04-10

Family

ID=75625652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559492A Withdrawn JP2023519962A (ja) 2020-03-31 2021-03-30 抗mertk抗体及びその使用方法

Country Status (5)

Country Link
US (1) US20240294650A1 (OSRAM)
EP (1) EP4126937A1 (OSRAM)
JP (1) JP2023519962A (OSRAM)
CN (1) CN116075525A (OSRAM)
WO (1) WO2021202590A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11505610B2 (en) 2018-04-06 2022-11-22 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
ES2978570T3 (es) 2019-02-26 2024-09-16 Inspirna Inc Anticuerpos anti-MERTK de alta afinidad y sus usos
CN114746120B (zh) 2019-10-03 2024-07-30 Atyr医药公司 包含抗nrp2抗体的组合物和方法
AU2020401319A1 (en) 2019-12-13 2022-06-30 Alector Llc Anti-MerTK antibodies and methods of use thereof
BR112023022975A2 (pt) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh Polipeptídeos de ligação ao antígeno bma031 melhorados
CA3217372A1 (en) * 2021-05-14 2022-11-17 Masoud TAVAZOIE Mertk peptides and uses thereof
JP2024540083A (ja) * 2021-10-27 2024-10-31 エータイアー ファーマ, インコーポレイテッド 抗NRP2a抗体を含む組成物及び方法
IL327260A (en) * 2023-09-25 2026-05-01 Astellas Pharma Inc Anti-MerTK agonist antibody, anti-MerTK bispecific antibody, and their use

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
ES2965283T3 (es) 2006-03-15 2024-05-28 Alexion Pharma Inc Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
SG10201913611QA (en) * 2014-08-08 2020-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
EP3789039A1 (en) 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
US10123621B2 (en) * 2015-11-19 2018-11-13 The Lovesac Company Furniture system recliner assembly with sled rails
WO2019084307A1 (en) * 2017-10-26 2019-05-02 Celldex Therapeutics, Inc. ANTI-MERTK ANTIBODIES AND METHODS OF USE
AU2018376379A1 (en) * 2017-11-30 2020-03-05 University Of Tsukuba Activity modulator
WO2020076799A1 (en) * 2018-10-09 2020-04-16 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
WO2020106461A2 (en) 2018-11-08 2020-05-28 Celldex Therapeutics, Inc. Anti-mertk antibodies and methods of use thereof
CN109678959B (zh) * 2019-02-22 2020-12-08 北京免疫方舟医药科技有限公司 抗cd40抗体及其应用
ES2978570T3 (es) * 2019-02-26 2024-09-16 Inspirna Inc Anticuerpos anti-MERTK de alta afinidad y sus usos
MX2021012692A (es) * 2019-04-19 2021-11-12 Genentech Inc Anticuerpos anti-mertk y sus metodos de uso.

Similar Documents

Publication Publication Date Title
JP7781859B2 (ja) 抗ror1抗体及び関連の二重特異性結合タンパク質
CN110156892B (zh) 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
JP2023506465A5 (OSRAM)
CN104936981B (zh) Il‑17a结合物及其用途
JP2022524588A5 (OSRAM)
JP2014509861A5 (OSRAM)
RU2009107494A (ru) АНТИТЕЛА К ErbB2
JP2018510636A5 (OSRAM)
JP2018527887A5 (OSRAM)
JP2022533538A5 (OSRAM)
CA3236138A1 (en) Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins
JP2013535970A5 (OSRAM)
JP2021534797A5 (OSRAM)
US11261246B2 (en) Anti-IL-22R antibodies
JP2019516392A5 (OSRAM)
JP2024541680A5 (OSRAM)
CA3183471A1 (en) Anti-b7h4 antibody, and bispecific antibody and use thereof
JP2025505650A5 (OSRAM)
JP2023531230A5 (OSRAM)
JP2019518473A5 (OSRAM)
RU2844869C1 (ru) Антитела против ror1 и родственные биспецифичные связывающие белки
US20250075000A1 (en) Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
US20260015430A1 (en) Antigen binding protein specific for transmembrane activator and caml interactor (taci)
RU2021112131A (ru) Антитела, нацеленные на epn1
WO2025024780A1 (en) Antibodies that bind gamma-delta t cell receptors for the treatment of cancer